193 related articles for article (PubMed ID: 28712622)
1. Pharmaceutical Pricing in Germany: How Is Value Determined within the Scope of AMNOG?
Lauenroth VD; Stargardt T
Value Health; 2017; 20(7):927-935. PubMed ID: 28712622
[TBL] [Abstract][Full Text] [Related]
2. Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.
Karnon J; Edney L; Sorich M
Aust Health Rev; 2017 Mar; 41(1):1-6. PubMed ID: 26954612
[TBL] [Abstract][Full Text] [Related]
3. Structural changes in the German pharmaceutical market: price setting mechanisms based on the early benefit evaluation.
Henschke C; Sundmacher L; Busse R
Health Policy; 2013 Mar; 109(3):263-9. PubMed ID: 23339876
[TBL] [Abstract][Full Text] [Related]
4. Lessons From The Impact Of Price Regulation On The Pricing Of Anticancer Drugs In Germany.
Lauenroth VD; Kesselheim AS; Sarpatwari A; Stern AD
Health Aff (Millwood); 2020 Jul; 39(7):1185-1193. PubMed ID: 32634355
[TBL] [Abstract][Full Text] [Related]
5. Impacts of regulated competition on pricing in Chinese pharmaceutical market under urban employee basic medical insurance.
Zhao M; Wu J
Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):311-320. PubMed ID: 27762144
[TBL] [Abstract][Full Text] [Related]
6. [Benefit Assessment and Price Negotiation Under AMNOG: Calculable Process or Unfair Poker Game?].
Radic D; Haugk S; Radic M
Gesundheitswesen; 2018 Jun; 80(6):573-579. PubMed ID: 27636366
[TBL] [Abstract][Full Text] [Related]
7. Predictors of negotiated prices for new drugs in Germany.
Gandjour A; Schüßler S; Hammerschmidt T; Dintsios CM
Eur J Health Econ; 2020 Sep; 21(7):1049-1057. PubMed ID: 32451745
[TBL] [Abstract][Full Text] [Related]
8. Early benefit assessment of pharmaceuticals in Germany: manufacturers' expectations versus the Federal Joint Committee's decisions.
Fischer KE; Stargardt T
Med Decis Making; 2014 Nov; 34(8):1030-47. PubMed ID: 25149822
[TBL] [Abstract][Full Text] [Related]
9. [The costs of new drugs compared to current standard treatment].
Ujeyl M; Schlegel C; Gundert-Remy U
Z Evid Fortbild Qual Gesundhwes; 2013; 107(7):461-7. PubMed ID: 24238023
[TBL] [Abstract][Full Text] [Related]
10. 10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?
Büssgen M; Stargardt T
Appl Health Econ Health Policy; 2023 Sep; 21(5):751-759. PubMed ID: 37249741
[TBL] [Abstract][Full Text] [Related]
11. [Pharmaceutical reference pricing in Germany: definition of therapeutic groups, price setting through regression procedure and effects].
Stargardt T; Schreyögg J; Busse R
Gesundheitswesen; 2005 Jul; 67(7):468-77. PubMed ID: 16103970
[TBL] [Abstract][Full Text] [Related]
12. Early benefit assessment for pharmaceuticals in Germany: lessons for policymakers.
Schlette S; Hess R
Issue Brief (Commonw Fund); 2013 Oct; 29():1-9. PubMed ID: 24171232
[TBL] [Abstract][Full Text] [Related]
13. The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany.
Dintsios CM; Beinhauer I
Health Econ Rev; 2020 Mar; 10(1):7. PubMed ID: 32172494
[TBL] [Abstract][Full Text] [Related]
14. Impact of cross-reference pricing on pharmaceutical prices: manufacturers' pricing strategies and price regulation.
Stargardt T; Schreyögg J
Appl Health Econ Health Policy; 2006; 5(4):235-47. PubMed ID: 17249840
[TBL] [Abstract][Full Text] [Related]
15. Endogenous versus exogenous generic reference pricing for pharmaceuticals.
Antoñanzas F; Juárez-Castelló CA; Rodríguez-Ibeas R
Int J Health Econ Manag; 2017 Dec; 17(4):413-432. PubMed ID: 28508248
[TBL] [Abstract][Full Text] [Related]
16. German Pharmaceutical Pricing: Lessons for the United States.
Rodwin MA; Gerke S
Int J Health Serv; 2022 Jan; 52(1):146-158. PubMed ID: 34668806
[TBL] [Abstract][Full Text] [Related]
17. Reference Pricing in Germany: Implications for U.S. Pharmaceutical Purchasing.
Robinson JC; Panteli D; Ex P
Issue Brief (Commonw Fund); 2019 Feb; 2019():1-8. PubMed ID: 30883061
[TBL] [Abstract][Full Text] [Related]
18. Indication-specific pricing of pharmaceuticals in the US healthcare system.
Pearson SD; Dreitlein WB; Henshall C; Towse A
J Comp Eff Res; 2017 Jul; 6(5):397-404. PubMed ID: 28699779
[TBL] [Abstract][Full Text] [Related]
19. Early benefit assessment of new drugs in Germany - results from 2011 to 2012.
Hörn H; Nink K; McGauran N; Wieseler B
Health Policy; 2014 Jun; 116(2-3):147-53. PubMed ID: 24472328
[TBL] [Abstract][Full Text] [Related]
20. [The German Pharmaceutical Market Reorganization Act (AMNOG) from an economic point of view].
Kaier K; Fetzer S
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Mar; 58(3):291-7. PubMed ID: 25566846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
